Transcend Capital Advisors LLC Has $1.01 Million Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Transcend Capital Advisors LLC decreased its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 1.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,835 shares of the company’s stock after selling 285 shares during the quarter. Transcend Capital Advisors LLC’s holdings in RxSight were worth $1,013,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of RXST. RA Capital Management L.P. grew its stake in RxSight by 1.1% in the first quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock valued at $177,581,000 after purchasing an additional 38,540 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of RxSight by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after purchasing an additional 40,500 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of RxSight by 34.5% during the 4th quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock worth $20,685,000 after purchasing an additional 131,701 shares during the last quarter. Victory Capital Management Inc. raised its holdings in RxSight by 108.6% in the 4th quarter. Victory Capital Management Inc. now owns 256,684 shares of the company’s stock valued at $10,349,000 after acquiring an additional 133,642 shares in the last quarter. Finally, Great Lakes Advisors LLC acquired a new position in RxSight in the 4th quarter valued at approximately $8,226,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Insider Activity

In other news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at approximately $816,906.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at approximately $816,906.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie Andrews sold 15,625 shares of RxSight stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $58.00, for a total value of $906,250.00. Following the transaction, the director now owns 30,287 shares of the company’s stock, valued at approximately $1,756,646. The disclosure for this sale can be found here. 9.36% of the stock is owned by corporate insiders.

RxSight Price Performance

Shares of RXST traded down $0.37 during midday trading on Monday, hitting $41.40. The stock had a trading volume of 500,739 shares, compared to its average volume of 480,434. The company has a 50 day simple moving average of $53.84 and a two-hundred day simple moving average of $53.47. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -31.25 and a beta of 1.19.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.08). The firm had revenue of $29.51 million during the quarter, compared to analyst estimates of $27.56 million. RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The business’s revenue for the quarter was up 68.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.42) EPS. Analysts forecast that RxSight, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Wells Fargo & Company upped their price target on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Needham & Company LLC increased their target price on RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Stifel Nicolaus decreased their price target on RxSight from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. BTIG Research increased their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Oppenheimer increased their price target on RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, May 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight has a consensus rating of “Buy” and a consensus target price of $65.14.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.